MabThera (rituximab) 500 mg ROCHE, The Netherlands

Interchangeable drugs with the same active ingredient:

• Mabthera
• Reditux
• Rituxim
• Acellbia

Indications.

• MabThera ® is indicated for adults in the following cases:
• non-Hodgkin's lymphoma
• Monotherapy of patients with stage III-IV follicular lymphoma who are resistant to chemotherapy or are in the stage of the second or subsequent relapses after chemotherapy.
• Treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisolone).
• Treatment of previously untreated stage III-IV follicular lymphoma in combination with chemotherapy.
• Maintenance therapy of follicular lymphomas after receiving a response to induction therapy.
• chronic lymphocytic leukemia
• Treatment of previously untreated and relapsed/refractory chronic lymphocytic leukemia in combination with chemotherapy. There are only limited data on efficacy and safety in patients previously treated with monoclonal antibodies, including MabThera® , or in patients refractory to previous treatment with MabThera plus chemotherapy.
• rheumatoid arthritis
• Treatment of severe rheumatoid arthritis (active form) in adults in combination with methotrexate when treatment with other disease-modifying antirheumatic drugs (FMDs) has failed or is intolerable, including treatment with one or more tumor necrosis factor inhibitors.
• When used in combination with methotrexate, MabThera ® reduces the rate of progression of destructive changes in the joints according to radiographic data and improves physical function.
• Granulomatosis with polyangiitis and microscopic polyangiitis
• Treatment of severe forms of active granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis in combination with corticosteroids to induce remission in adult patients
• 500ct